Hematopoietic stem cell softening mediates mobilization due to AMD3100, thereby increasing count in peripheral blood

Thumbnail Image
Laohapant, Alvin
Associated Organizations
Supplementary to
Hematopoietic stem cells (HSCs) have the ability to differentiate into any blood cell as well as self-renew, giving rise to their pluripotent attribute. With the ability to differentiate, HSCs have the potential to be transplanted from healthy donors to matched patients with hematological malignancies as well as bone marrow failure. While the bulk of HSCs are located within the bone marrow, mobilization into the peripheral blood is required for accessible collection of HSCs, which ultimately eliminates the need for surgical procedures. Previous research findings have found that hematopoietic growth factor cytokines, more specifically Granulocyte colony-stimulating factor (G-CSF), as well as the mobilizing agent, plerixafor (AMD3100) increase mobilization of HSCs into the peripheral blood. While G-CSF and AMD3100 have both been scientifically proven and approved to increase HSC mobilization, the mechanical properties of HSCs have yet to be observed when mobilizing from the bone marrow to the peripheral blood. Here we use HSCs flowing through a microfluidic model to represent mobilization and hope to see cell softening due to AMD3100 during transit through the microfluidic device. By investigating the mechanical properties of HSCs during mobilization in the presence of AMD3100, clinical significance can lead to further studies as well as alternative mobilization techniques for use with HSC transplantation for patients with hematological malignancies as well as bone marrow failure.
Date Issued
Resource Type
Resource Subtype
Undergraduate Thesis
Rights Statement
Rights URI